HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1003-1009

  Johannessen, Asgeir ^a   Holberg Petersen, Mona ^a   Lövgaarden, Gunilla ^a   Naman, Ezra ^b   Ormaasen, Vidar ^a   Matee, Mecky I ^c   Gundersen, Svein G ^d,e   Bruun, Johan N ^a,f,g  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b HAYDOM LUTHERAN HOSPITAL   (Tanzania)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d Sørlandet Hospital   (Norway)

^e UNIVERSITY OF AGDER   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DESICCANT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOTS; DRUG TREATMENT FAILURE; ENVIRONMENTAL TEMPERATURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC RESISTANCE; GENOTYPE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; NONHUMAN; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RURAL AREA; SCHOOL CHILD; STORAGE TEMPERATURE; TANZANIA; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TYPING;

EID: 78651085389     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1660     Document Type: Article

References (34)

1. World Health Organization. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Geneva: World Health Organization 2009.
2. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303-2311.
3. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148. (Pubitemid 41669003)
4. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
5. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
6. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452. (Pubitemid 46147631)
7. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
8. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001; 131:1631S-1636S.
9. Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 2003; 41:1888-1893.
10. Lofgren SM, Morrissey AB, Chevallier CC, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS 2009; 23:2459-2466.
11. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-2511.
12. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-113.
13. McNulty A, Jennings C, Bennett D, et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 2007; 45:517-521. (Pubitemid 46272071)
14. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 Genotyping Assay. J Clin Virol 2008; 41:283-287.
15. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008; 61:1217-1220.
16. Garcia-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, Bremer JW. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother 2009; 64:33-36.
17. Hearps AC, Ryan CE, Morris LM, Plate MM, Greengrass V, Crowe SM. Stability of dried blood spots for HIV-1 drug resistance analysis. Curr HIV Res 2010; 8:134-140.
18. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Geneva: World Health Organization 2002.
19. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva: World Health Organization 2004.
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Geneva: World Health Organization 2006.
21. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
22. Nyombi BM, Kristiansen KI, Bjune G, Muller F, Holm-Hansen C. Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Hum Retroviruses 2008; 24:761-769.
23. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
24. Whatman, Ltd. 903 Protein Saver Cards. (Updated 6 May 2009. Accessed 6 May 2009.) Available from http://www.whatman.com/903ProteinSaverCards.aspx
25. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
26. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods 2006; 136:238-247.
27. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008; 13 Suppl 2:49-57.
28. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003; 34:1-6.
29. Venturi G, Romano L, Carli T, et al. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir Ther 2002; 7:245-250. (Pubitemid 36427128)
30. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-134.
31. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 1998; 36:258-260. (Pubitemid 28047472)
32. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol 2009; 47:1031-1036.
33. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009; 49:976-981.
34. Mbida AD, Sosso S, Flori P, et al. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J Acquir Immune Defic Syndr 2009; 52:9-16.